Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Multi-center study finds therapy boosts kidney transplants in ’highly sensitized’ patients

09.12.2004


Although transplantation is by far the preferred treatment option for patients with end-stage renal disease (ESRD), those with high levels of "anti-donor" antibodies have had little hope of receiving a donated organ. Among the relatively few who have undergone transplantation, rejection rates have been very high.



Because the immune systems of "highly sensitized" individuals initiate a rejection response against the tissue of the majority of the population, these patients typically spend the rest of their lives undergoing kidney dialysis several times a week – a painful, costly process that extends life but usually results in a diminishing quality of life.

Now, a 12-center study, funded in part by the National Institutes of Health and reported in the December 2004 issue of the Journal of the American Society of Nephrology, found that an immune-modulating therapy pioneered for transplant patients at Cedars-Sinai Medical Center reduced high antibody levels and improved transplantation rates. The analysis was based on the experiences of 98 highly sensitized patients who were administered either the medication, called intravenous immunoglobulin (IVIG), or a placebo while awaiting transplantation.


"The study showed that there was a significant benefit of IVIG over placebo. In fact, the rates of transplantation for the IVIG group were more than double that for the placebo group. And for patients who had had a previous transplant – which is a very big risk factor for not being able to have another one – the IVIG group’s transplant rate was triple that of patients on placebo," said Stanley C. Jordan, MD, director of Pediatric Nephrology & Transplant Immunology and medical director of the Renal Transplant Program at Cedars-Sinai.

"Most other anti-rejection drugs can make the patient more susceptible to infectious complications because they are globally immunosuppressive," said Dr. Jordan, the study’s principal investigator, the article’s senior author and a professor of pediatrics at the University of California, Los Angeles. "The good thing about IVIG is that it modulates the immune system, it doesn’t suppress it. It appears to ’turn off’ deleterious immune responses without damaging the immune system, and in fact, it strengthens the immune system because it provides antibodies to infectious agents as well."

Although tissue compatibility issues exist for all patients receiving transplanted organs, rejection risks are especially high for a patient who has the added barrier of an immune system that has been exposed to "non-self" human leukocyte antigens (HLAs). Exposure may occur through blood transfusions, earlier organ transplantation or even pregnancy, when the mother is exposed to antigens from the father expressed in the cells of the developing baby. The immune system is then "sensitized" to those antigens – primed with antibodies to attack, even if the antigens arrive in the form of a potentially life-saving donated organ.

The degree of sensitization is measured in terms of "panel reactive antibody" or PRA levels. For a non-sensitized patient with end-stage renal disease, the wait time for a cadaveric transplantation averages four to five years. For sensitized patients, the odds of being transplanted drop. According to the article, "the higher the PRA, the more difficult it becomes to find an immunologically compatible match. Transplant rates are lower for sensitized patients and the waiting times for a compatible crossmatch are longer. Furthermore, while many of these patients may have living donors, transplantation cannot proceed …."

In 2000, fewer than 3 percent of all kidney transplants were performed in patients with PRAs higher than 80 percent at the time of transplant, despite the fact that these patients represent about 20 percent of those on the waiting list. In fact, transplant rates for these patients have gone down over the past decade as antibody detection techniques improved and waiting lists for the limited number of donor organs grew.

Dr. Jordan began to develop the concept of using immunoglobulins in a transplant environment in the late 1980s as IVIG was becoming established as a therapy for immune system disorders. The proteins, naturally produced in the body, can act as antibodies – natural defenses against invading organisms called antigens. A processed form of immunoglobulin made from blood plasma can be administered to boost the body’s natural levels.

Researchers led by Dr. Jordan have published several studies showing that IVIG therapy increases success rates for patients receiving cadaver organs as well as organs donated by relatives or friends. They also have developed a lab test that enables them to predict which patients will most likely benefit from IVIG. If IVIG changes a poor match into a more compatible one in the lab, it likely will help the patient’s immune system accept a transplanted organ.

The new study results showing that IVIG can make transplantation available to many patients who previously would have lingered on dialysis comes just months after some Medicare and other insurance providers began offering coverage for IVIG therapy in certain situations. Using IVIG to get even half of the sensitized patients transplanted and off of long-term dialysis would bring huge savings, according to cost analyses.

"From a financial standpoint and from a quality of life standpoint, there is no question that IVIG therapy and transplantation have more to offer than years of dialysis," Dr. Jordan said.

Sandra Van | EurekAlert!
Further information:
http://www.cedars-sinai.org

More articles from Studies and Analyses:

nachricht Smart Data Transformation – Surfing the Big Wave
02.12.2016 | Fraunhofer-Institut für Angewandte Informationstechnik FIT

nachricht Climate change could outpace EPA Lake Champlain protections
18.11.2016 | University of Vermont

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Electron highway inside crystal

Physicists of the University of Würzburg have made an astonishing discovery in a specific type of topological insulators. The effect is due to the structure of the materials used. The researchers have now published their work in the journal Science.

Topological insulators are currently the hot topic in physics according to the newspaper Neue Zürcher Zeitung. Only a few weeks ago, their importance was...

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Researchers identify potentially druggable mutant p53 proteins that promote cancer growth

09.12.2016 | Life Sciences

Scientists produce a new roadmap for guiding development & conservation in the Amazon

09.12.2016 | Ecology, The Environment and Conservation

Satellites, airport visibility readings shed light on troops' exposure to air pollution

09.12.2016 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>